drugset
drugset / Trial / NCT03594422

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

NCT03594422 ↗

Phase 1 Recruiting 100 enrolled Ascentage Pharma Group Inc. HealthQuest Pharma Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.

Timeline

Start
2018-07-11
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olverembatinib Small molecule 20 mg Oral
Subject Olverembatinib Small molecule 30 mg Oral
Subject Olverembatinib Small molecule 40 mg Oral
Subject Olverembatinib Small molecule 50 mg Oral

Indications

cancer gastrointestinal stromal tumor